The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12611000674932
Ethics application status
Approved
Date submitted
29/04/2011
Date registered
4/07/2011
Date last updated
28/06/2018
Type of registration
Retrospectively registered

Titles & IDs
Public title
A randomised, cross-over trial of upright sitting versus alternate side lying during nebulised delivery of medication to improve the pattern of aerosol deposition in healthy participants
Scientific title
A randomised, cross-over trial of upright sitting versus alternate side lying during nebulised delivery of medication to improve the pattern of aerosol deposition in healthy participants
Secondary ID [1] 260082 0
Nil
Universal Trial Number (UTN)
U1111-1121-1087
Trial acronym
Nil
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Healthy participants (to be compared to participants with cystic fibrosis of a similar age) 265754 0
Condition category
Condition code
Respiratory 265901 265901 0 0
Normal development and function of the respiratory system
Human Genetics and Inherited Disorders 268351 268351 0 0
Cystic fibrosis

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Participants will inhale 4mL technetium-99m DTPA radioaerosol in two positions in random order throughout the nebulisation period of 20 minutes for each of the positioning regimens on two separte days: 1. Upright sitting: or 2. Alternate Side Lying: (alternated between left and right at each minute)
The two study days will have a minimum of 48 hours washout between them and not greater than 7 days (to ensure clinical stability).
After each nebulisation a gamma camera will perform a 20 minute deposition scan incorporating a 2 minute transmission scan to outline the three-dimensional margin of the lung fields. This data will be reconstructed to determine the distribution of the deposited radioaerosol in the lungs.
Intervention code [1] 264498 0
Treatment: Other
Intervention code [2] 266894 0
Treatment: Devices
Comparator / control treatment
Upright sitting is the control condition, alternate side lying the experimental
Control group
Active

Outcomes
Primary outcome [1] 266663 0
The 3-dimensional map of the lung fields will be divided into unit volumes (voxels). The amount of radioactivity in each voxel will be calculated. The standard deviation of the radioactivity across all voxels within the margins of the lung fields will be used as an index of uniformity of the pattern of deposition for each participant.
Timepoint [1] 266663 0
Immediately post 20 minutes of inhalation
Secondary outcome [1] 276157 0
Proportion of the loaded dose (dose loaded in nebuliser - residual remining in nebuliser post 20 minutes of inhalation in MBq) delivered to the body (decay corrected gamma camera body image dose in MBq).
Timepoint [1] 276157 0
Immediately post 20 minutes of inhalation
Secondary outcome [2] 276158 0
The proportion of the delivered dose (dose loaded in nebuliser - residual remining in nebuliser post 20 minutes of inhalation in MBq) that deposited in the lungs. (decay corrected lung gamma camera image dose in MBq).
Timepoint [2] 276158 0
Immediately post 20 minutes of inhalation
Secondary outcome [3] 276973 0
The concentration of the dose in the apical regions compared to the concentration for the whole lung. The 3-dimensional map of the lung fields will be divided into unit volumes (voxels). The amount of radioactivity in each voxel will be calculated. The ratio of apical:non-apical deposition of radioactivity will be determined by the mean number of counts per voxel in the apical one third of the lung field divided by the mean number of counts per voxel in the basal two thirds of the lung field.
Timepoint [3] 276973 0
Immediately post 20 minutes of inhalation

Eligibility
Key inclusion criteria
Inclusion Criteria: To participate in this study, a person must:
1 be 18 years of age or older
2 be able to read, write and comprehend English
3 have normal lung function, with greater than or equal to 80% predicted FEV1
4 be willing to inhale a 4mL radioaerosol and undergo a 20-minute gamma scan, on two occasions.
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
Exclusion Criteria: A person will be ineligible to participate in this study if s/he:
1 has any respiratory condition
2 has significant malignant, neurological or musculoskeletal conditions
3 is unable to perform spirometry reproducibly
4 is pregnant, or is sexually active and unwilling to use contraception during the study
5 is in a dependent relationship to any of the investigators, eg. student, junior staff.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Potential participants will be invited to read an Information for Participants document, and sign a consent form to participate in the study. Eligibility will then be confirmed with reference to the willing participant’s spirometry in standing according to the most recent American Thoracic Society criteria
Participants will then be randomised via a coin toss to one of:
1. Upright sitting: to be maintained throughout the nebulisation period of 20 minutes, or
2. Alternate Side Lying: to be alternated between left and right at each minute during the nebulisation period of 20 minutes.
Participants will be requested to adopt this position and maintain a normal tidal breathing pattern during the subsequent standard study inhalation. When participants return for their second study day, they will adopt the other positioning regimen.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Coin toss for first position
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Coin toss for first of the two sidelying positions
Phase
Not Applicable
Type of endpoint(s)
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW

Funding & Sponsors
Funding source category [1] 264977 0
Charities/Societies/Foundations
Name [1] 264977 0
Australian CF Research Trust Post-Graduate Award.
Address [1] 264977 0
P.O. Box 254
North Ryde NSW 1670
Country [1] 264977 0
Australia
Primary sponsor type
Hospital
Name
Royal Prince Alfred Hospital
Address
Level 3, Building 92 RPAH
Missenden Road
Camperdown NSW 2050
Country
Australia
Secondary sponsor category [1] 264067 0
None
Name [1] 264067 0
Address [1] 264067 0
Country [1] 264067 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 266936 0
SSWAHS (RPA Zone)
Ethics committee address [1] 266936 0
Level 3 Building 92 RPAH
Missenden Road
Camperdown NSW 2050
Ethics committee country [1] 266936 0
Australia
Date submitted for ethics approval [1] 266936 0
Approval date [1] 266936 0
03/03/2009
Ethics approval number [1] 266936 0
Protocol No X09-0017 & HREC/09/RPAH/25

Summary
Brief summary
Participants will inhale a 4mL radioaerosol in two positions in random order throughout the nebulisation period of 20 minutes: 1. Upright sitting: or
2. Alternate Side Lying: (alternated between left and right at each minute)
After each nebulisation a gamma camera will perform a 20-minute deposition scan incorporating a 2-minute transmission scan to outline the three-dimensional margin of the lung fields. This data will be reconstructed to determine the distribution of the deposited radioaerosol in the lungs. A 15% improvement in uniformity of deposition is the proposed minimum difference that would make further investigation of the alternate side lying strategy worthwhile in patient populations.

Significance of project: In many patient populations (eg, cystic fibrosis, HIV and bronchiectasis), the pattern of deposition of inhaled medication is poor and non-uniform. Typically the upper lobes receive a reduced dose compared to the rest of the lung. The ability to deliver a drug more uniformly to the lung using a strategy of side lying may have a significant impact on treatment efficacy for people with lung disease. Data from healthy participants will aid interpretation of subsequent studies in patients.
Trial website
Nil
Trial related presentations / publications
Nil
Public notes

Contacts
Principal investigator
Name 32550 0
Dr Ruth Dentice
Address 32550 0
Department of Respiratory Medicine Level 11 Royal Prince Alfred Hospital Missenden Road Camperdown NSW 2050
Country 32550 0
Australia
Phone 32550 0
61 2 95155234
Fax 32550 0
Email 32550 0
ruth.dentice@health.nsw.gov.au
Contact person for public queries
Name 15797 0
Dr Ruth Dentice
Address 15797 0
Department of Respiratory Medicine Level 11
Royal Prince Alfred Hospital
Missenden Road Camperdown NSW 2050
Country 15797 0
Australia
Phone 15797 0
61 2 95155234
Fax 15797 0
61 2 95158196
Email 15797 0
ruth.dentice@health.nsw.gov.au
Contact person for scientific queries
Name 6725 0
Dr Ruth Dentice
Address 6725 0
Department of Respiratory Medicine Level 11
Royal Prince Alfred Hospital
Missenden Road Camperdown NSW 2050
Country 6725 0
Australia
Phone 6725 0
61 2 95155234
Fax 6725 0
61 2 95158196
Email 6725 0
ruth.dentice@sswahs.nsw.gov.au

No information has been provided regarding IPD availability
Summary results
Have study results been published in a peer-reviewed journal?
Other publications
Have study results been made publicly available in another format?
Results – basic reporting
Results – plain English summary